<amendment session="108" chamber="s" number="974" updated="2022-02-03T04:58:55Z">
  <amends type="s" number="1" sequence=""/>
  <status datetime="2003-06-25">pass</status>
  <sponsor bioguide_id="G000386"/>
  <offered datetime="2003-06-20"/>
  <description>To enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding brand name drugs and generic drugs.</description>
  <actions>
    <vote datetime="2003-06-25" how="Voice Vote" result="pass">
      <text>Amendment SA 974 agreed to in Senate by Voice Vote.</text>
    </vote>
    <action datetime="2003-06-25">
      <text>Considered by Senate.</text>
      <reference ref="CR S8480, S8538" label="consideration"/>
    </action>
    <action datetime="2003-06-24">
      <text>Considered by Senate.</text>
      <reference ref="CR S8386, S8430-8431" label="consideration"/>
    </action>
    <action datetime="2003-06-23">
      <text>Amendment SA 974 proposed by Senator Grassley. (consideration: CR S8351-8352; text: CR S8351) To enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding brand name drugs and generic drugs.</text>
    </action>
    <action datetime="2003-06-25">
      <text>Senate amendment agreed to: Amendment SA 974 agreed to in Senate by Voice Vote.</text>
    </action>
    <action datetime="2003-06-23">
      <text>Senate amendment proposed (on the floor): Amendment SA 974 proposed by Senator Grassley.</text>
      <reference ref="CR S8351-8352" label="consideration"/>
      <reference ref="CR S8351" label="text"/>
    </action>
    <action datetime="2003-06-20">
      <text>Senate amendment submitted</text>
    </action>
  </actions>
</amendment>
